NCT04121481

Brief Summary

This pilot investigation will conduct a randomized placebo-controlled, double-blind study in 150 volunteers (age: 18-74 years) over a period of 90 consecutive days. A statistician will be involved in this project. Body weight, body mass index (BMI), waist circumference, blood chemistry, blood pressure and heart rate, body and hand grip strength, speed and endurance studies including open circuit spirometry-based assessment of pulmonary function will be assessed. Other parameters to be evaluated include oxygen consumption, CO2 production and metabolic parameters, VO2 max, respiratory exchange ratio (RER), anaerobic threshold, ventilatory equivalents for oxygen (VE/V02) and exhaled carbon dioxide (VE/VC02)2,3. Subjects will participate in completed maximal graded exercise tests (GXT) on a treadmill or in set distance open-field sprints using open-circuit spirometry. Lower and Upper Body Strength will be evaluated. E-Diary will be provided to all participants. Survey Monkey program will be provided to all subjects and regularly updated by all study participants daily and endorsed by the co-Principal Investigator.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 10, 2019

Completed
1.6 years until next milestone

Study Start

First participant enrolled

May 15, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2022

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

May 7, 2021

Status Verified

May 1, 2021

Enrollment Period

9 months

First QC Date

October 3, 2019

Last Update Submit

May 5, 2021

Conditions

Keywords

Prodovite VMP35; RCT; Athletic Performance

Outcome Measures

Primary Outcomes (10)

  • Anthropometric Measurements: Body Weight

    Body Weight (Kilograms)

    Over a Period of 90-Consecutive Days

  • Anthropometric Measurements: Height

    Height (Meters)

    Over a Period of 90-Consecutive Days

  • Anthropometric Measurements: Waist Circumference

    Waist Circumference (Meters)

    Over a Period of 90-Consecutive Days

  • Anthropometric Measurements: Waist-Hip Ratio

    Waist : Hip Ratio

    Over a Period of 90-Consecutive Days

  • Anthropometric Measurements: Blood Pressure (mmHg)

    Blood Pressure (mmHg)

    Over a Period of 90-Consecutive Days

  • Body Composition and Bone Mineral Density: DEXA (GE)

    DEXA and Bone Mineral Density

    Over a Period of 90-Consecutive Days

  • Ergometric Assessment: Treadmill

    Ergometric measurements

    Over a Period of 90-Consecutive Days

  • Handgrip Dynamometer

    Handgrip strength

    Over a Period of 90-Consecutive Days

  • Respiration Quality and Rate: Spirometer

    Respiration Quality, VO2 and VCO2 assessments

    Over a Period of 90-Consecutive Days

  • Endurance Studies

    Cycle Ergometer, Bench Press and Leg Press

    Over a Period of 90 Consecutive Days

Secondary Outcomes (2)

  • Lipid Profile

    Over a Period of 90-Consecutive Days

  • Total Blood Chemistry

    Over a Period of 90-Consecutive Days

Study Arms (2)

Placebo

PLACEBO COMPARATOR

Approximately a total of 75 participants will be assigned in the Placebo Group (two divided doses will be given)

Dietary Supplement: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 SupplementDietary Supplement: Broad Spectrum Safety

Treatment Group

ACTIVE COMPARATOR

Approximately a total of 75 participants will be assigned in the Treatment Group (two divided doses will be given) Adverse Event Monitoring will be Strictly Enforced

Dietary Supplement: Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 SupplementDietary Supplement: Broad Spectrum Safety

Interventions

Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample

Also known as: Physical Well Being, Health Status, Detailed Lipid Profile and Blood Chemistry Analysis; Adverse Event Monitoring; Compliance
PlaceboTreatment Group
Broad Spectrum SafetyDIETARY_SUPPLEMENT

Benefits in Sports Nutrition

Also known as: Sports Nutrition and Health Staus
PlaceboTreatment Group

Eligibility Criteria

Age18 Years - 74 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Agrees to written as well as audio-visual informed consent
  • Ability to understand the risks/benefits of the study protocol
  • Healthy male and female, human subjects 18-74 years of age
  • Subjects experienced with at least six months of regular athletic performance training
  • AND
  • Uncooperative Subjects
  • Subjects with chronic illness (diabetes, cardiovascular disease, cancer, arthritis, etc) or those on prescription medication excluded (except for birth control pills)
  • Any conditions that prevent the subject from participating in physical activities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Champions Sports Performance & Hardcore Serious Fitness

Cornelius, North Carolina, 28031, United States

RECRUITING

Related Publications (1)

  • Corbier JR, Downs BW, Kushner S, Aloisio T, Bagchi D, Bagchi M. VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis. Food Nutr Res. 2019 May 9;63. doi: 10.29219/fnr.v63.3410. eCollection 2019.

MeSH Terms

Interventions

Health StatusCompliance

Intervention Hierarchy (Ancestors)

DemographyPopulation CharacteristicsEpidemiologic MeasurementsPublic HealthEnvironment and Public HealthElasticityMechanical PhenomenaPhysical Phenomena

Study Officials

  • BRUCE S MORRISON, DO

    SPORTS NUTRITION & FAMILY MEDICINE

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Double-Blind Placebo-Controlled Study
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: The aim of this pilot study is to evaluate the effect of oral supplementation of Prodovite® VMP35 on exercise endurance, muscle strength, anabolic parameters and lean body mass in healthy human subjects. We hypothesize that Prodovite® VMP35 supplementation will enhance and increase exercise performance, tolerance, lean-body muscle mass, improve anabolic parameters and blood chemistry parameters in healthy human subjects. Accordingly, 150 healthy male and female subjects will be randomly assigned to receive either Prodovite® VMP35 or placebo in the form of single dose sealed containers for 90 consecutive days and muscle strength, endurance, speed, anabolic/catabolic parameters and muscle mass will be evaluated by dual energy X-ray absorptiometry (DEXA), hand-grip strength test, cycle ergometer test, spirometer assessment and assay of Blood chemistry and serum biomarkers will be evaluated before and after intervention.
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 3, 2019

First Posted

October 10, 2019

Study Start

May 15, 2021

Primary Completion

January 31, 2022

Study Completion

September 30, 2022

Last Updated

May 7, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will not share

IT IS A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY

Locations